blu-554
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02508467)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast growth factor receptor 4INHIBITOR
FGFR4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- blu-554
- blu-554
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04194801 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2019 | CStone Pharmaceuticals |
| NCT02508467 | Phase 1 | Jul 1, 2015 | Blueprint Medicines Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blueprint Medicines Corporation | For profit | 1 | 1 | 1 | 2015 |
| CStone Pharmaceuticals | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1